NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON

Vendor Intelligence Report: Zenith Jove Peptide ZJ

Published 12 Nov 2026. 36-page investigative report on who is behind Zenith Jove Peptide ZJ: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Zenith Jove Peptide ZJ is now a channel-authentication problem, not just a lab-results problem. Across 91 Finnrick lab tests, the overall pass rate is 81% (74 pass / 17 fail), but the record splits sharply by product. GHK-Cu and Retatrutide are the stronger ZJ signals, while TB-500 and Tesamorelin are weak choices; Tirzepatide has depth but remains mixed. The full report breaks out the product-level and methodology-sensitive view without treating the vendor as one uniform result.

The larger finding is that ZJ's current official channel could not be verified. The GLP-1 Forum slot is archived under inactive vendors, the last visible promotion is from August 2026, a later full-store-sale thread is unavailable, and zjpeptide.com expired, was re-registered by an unidentified holder, and now points to a parking/for-sale page. That breaks the former authentication anchor for any buyer approached through WhatsApp, Telegram, TikTok, or a stale search result.

The report also treats the unlabeled-vial correction as a catalog-wide practical hazard: a Tirzepatide-submitted sample was found to contain Semaglutide after a reported mix-up, and Finnrick specifically flags unlabeled vials as the use-risk. ZJ's public group-test promise is a favorable sign of testing culture, but no public registry extract, UBO, verified manufacturer, QA officer, or batch-release authority was established in the reviewed sources.

Adjacent surfaces complicate the picture without resolving it. A ZLZ-branded TikTok handle uses Zenith Jove wording, Kerui remains a nearby supplier-environment lead, and SEO-spam pages republish ZJ fragments, but the report does not find a verified rebrand or sister company. For historical stock or a claimed resale, the buyer read is product-specific, batch-specific, and channel-specific.

Inside the full report:

  • Complete Finnrick product-by-methodology lab data and divergence charts for all 9 products
  • Domain-lifecycle evidence spanning Xinnet RDAP, Verisign re-registration, Above.com parking, and GoDaddy sale listing
  • GLP-1 Forum chronology from launch through inactive-vendor archive and the unavailable August sale thread
  • Representative-channel map covering Zora, Lydia, Cici, Kiki, WhatsApp, Telegram, Gmail, and TikTok surfaces
  • Corporate identity and UBO assessment for Guangzhou ZJ Biotechnology Co., Ltd. / 广州ZJ生物技术有限公司
  • ZLZ, Kerui, lookalike-domain, and SEO-spam adjacency analysis with confidence levels

Risk assessment

  • Vendor inactivity / no verified live channel — high: ZJ's last visible forum post is 13 Aug 2026; GLP-1 Forum lists ZJ under Archived/Inactive Vendors; zjpeptide.com is parked/for sale, leaving no verified current ordering or remedy channel.
  • Channel-confusion and impersonation risk — high: The former official domain is for sale, TikTok signals changed or vanished, SEO-spam pages republish stale contacts, and no canonical official-channel registry was verified.
  • Molecule-identification risk from unlabeled vials — high: Whole catalog: Finnrick correction record says a Tirzepatide-submitted sample contained Semaglutide after a mix-up and flags unlabeled vials.
  • TB-500 weak testing risk — high: TB-500: 4 tests, 2 pass / 2 fail, 40.75%; buyers should not transfer confidence from stronger ZJ products.
  • Tesamorelin weak testing risk — high: Tesamorelin: 4 tests, 2 pass / 2 fail, 47.86%; the current signal is fail-heavy.
  • Tirzepatide mixed testing risk — high: Tirzepatide: 24 tests, 18 pass / 6 fail, 74.56%; materially weaker than ZJ Retatrutide.
  • BPC-157 weaker-testing risk — medium: BPC-157: 10 tests, 9 pass / 1 fail, 67.98%; below ZJ's stronger GHK-Cu and Retatrutide signals.
  • Cagrilintide thin/fail testing risk — medium: Cagrilintide: 3 tests, 2 pass / 1 fail, 56.85%; one failure in a very small sample.
  • Ownership and manufacturing-transparency gap — medium: The Guangzhou ZJ Biotechnology identity is public, but no registry extract, legal representative, shareholders, UBO, verified factory, or batch-release authority was located.
  • Payment-recourse risk — medium: Representative-led ordering and crypto rails limit recovery; the PayPal claim does not verify merchant identity or buyer-protection eligibility, and no active checkout was verified.
  • U.S.-warehouse substantiation risk — medium: ZJ advertised U.S.-warehouse shipping, but no U.S. entity, warehouse address, consignee, or fulfillment partner was verified.